Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 9, Issue 4, Pages 481-491Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590902828285
Keywords
Alzheimer's disease; amyloid; passive immunization
Funding
- NIH/NIA [1 P30 AG028383, 2R01AG019241-06A2]
- NIH LRP [1 L30 AG032934-01]
- Alzheimer's Association [NIRG-07-59967]
- Sanders-Brown Foundation
- NIHNIA ADCS [UOIAGO10483]
Ask authors/readers for more resources
Background: Passive immunization strategies are under investigation as potential disease-modifying therapies for Alzheimer's disease (AD). Current approaches, based on data demonstrating behavioral improvement and reduced pathology in transgenic animal models, have focused exclusively on immune targeting of beta-amyloid. Objective: To examine immunization strategies for AD. Methods: A review of relevant publications. Results/conclusions: Preliminary results from three Phase II trials suggest both the promise and the need to exercise caution with this method of immunotherapy. The strategies used were distinct, using monoclonal N-terminal, central epitope, and polyclonal antibodies to maximize the efficacy and safety of each approach. The tested compounds are moving into Phase III trials for mild to moderate AD. We await the discoveries that from these studies that may yield the first disease-modifying therapy for AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available